将基于TCR的化学抗原受体STAR转化为用于癌症免疫治疗的双特异向受体
Li Yu1, Zhixiao Zhou2, Hanyang Yu3
1Changping Laboratory, Beijing 102206, China.
概括
一种新型的双向合成T细胞受体和抗原受体 (D-STAR) 显示出对B细胞恶性瘤的增强疗效. 这种工程T细胞疗法克服了当前仿真抗原受体 (CAR) T细胞治疗中的挑战,提供了卓越的抗瘤活性.
科学领域:
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
- 细胞工程 细胞工程
背景情况:
- 化学抗原受体 (CAR) T细胞疗法对血液癌症有效,但在复发方面面临挑战.
- 当前的多特异性CAR工程方法可能会导致由于scFv安排的聚合问题.
研究的目的:
- 开发一种新的化学受体,D-STAR,具有改善的结构性质和增强的抗瘤活性.
- 在B细胞恶性瘤的临床前模型中评估D-STAR T细胞的疗效.
主要方法:
- 开发双准合成TCR和抗原受体 (D-STAR) 结构.
- 在体外评估T细胞激活和效应器功能.
- 在B细胞恶性瘤的小鼠模型中的体内疗效研究.
- 整合OX40共刺激域以增强T细胞适应性.
主要成果:
- D-STAR证明了结构上的优势,并有效地激活T细胞.
- D-STAR调解了各种恶性B细胞的强有力的杀死.
- 与传统的CAR-T细胞相比,D-STAR在小鼠模型中显示出更高的抗瘤疗效.
- 用OX40增强的D-STAR改善了T细胞的增殖和健康状况,特别是在高瘤负担下.
结论:
- D-STAR代表了一种用于T细胞治疗的新且具有结构优势的嵌合体受体.
- D-STAR T细胞对B细胞恶性瘤具有强大的抗瘤活性.
- D-STAR平台提供了一个有前途的策略,以克服CAR T细胞治疗中的复发挑战.
关键词:
在CART-T中,我们可以使用CAR-T.在 D-STAR 系统中,D-STAR 是在OX40中,OX40是什么?T细胞的增殖和扩散.免疫疗法 免疫疗法恶性瘤是一种恶性瘤.治疗后复发的治疗后复发更多相关视频
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
53.1K
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.6K
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
01:27Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464